3692
Economical advantages of insulin analogues use in basal-bolus regimen for the therapy of type 1 diabetes mellitus
According to the first Global Report of the WHO, diabetes mellitus is an important public health problem, one of four priority noncommunicable diseases (NCDs) targeted for action by world leaders. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades. In the estimation of the WHO, 422 million adults were living with diabetes in 2014, compared to 108 million in 1980. The global prevalence (age-standardized) of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Arinina E.E., Rashid M.A. Economical advantages of insulin analogues use in basal-bolus regimen for the therapy of type 1 diabetes mellitus // Pharmacoeconomics: theory and practice. - 2017. - Vol.5, №1. - P.52-55 DOI: https://doi.org/10.30809/phe.1.2017.28
Comments0